Search Results for: refractory multiple myeloma
ASGCT 2024 ASGCT Previews
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Trending Drug PricingDrug ManufacturingMedication
New Trends of Hospital Pharmacy Expenditure: Specialty and Neurology Medications are Escalating
2023-08-09
Special ASCOOncology
2023 ASCO Annual Meeting: Breakthroughs in Cancer Care and Advances in CAR T-cell Therapy
2023-07-11
Trials & Approvals Multiple Myeloma DrugArcellx
Clinical Hold Announced for Arcellx’s IMMagine-1 Phase 2 Clinical Program
2023-06-27
Trials & Approvals CAR T-cell TherapyKite Pharma
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
2023-03-22
Oricell Closes $45M Series B1 Financing to Expand Development of Key Products
2023-02-28
China CAR T-cell Therapy
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
2023-01-17
Go Prime Gene Therapy
Will Breakthrough Therapy Lead the Way? An Overview of the Approved Gene and Cell Therapies for 2022
2023-01-13
Special American Society of Hematology
64th ASH Annual Meeting and Exposition: Broad Coverage of Clinical, Social, and Nutritional Issues
2023-01-04
Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma
2022-12-22
Special ASH
64th ASH Annual Meeting and Exposition: Discoveries That Reinvent Blood Disease Treatments
2022-12-20
CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting
2022-12-12
Partnerships CAR T-cell Therapy
Kite And Arcellx Join Forces for Developing Cell Therapy targeting Multiple Myeloma
2022-12-12
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
2022-11-21
ASH 2022 | Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of 98%, in an Oral Report at the ASH Annual Meeting
2022-11-03
1 2 3 4
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top